Mib-1 evaluated proliferative activity in ovarian cancer with respect to prognostic significance

Anticancer Research

Volumn 17, Issue 1 B, 1997, Pages 775-780

  Marx, Dagmar ^a   Meden, H ^a   Brune, T ^a   Kron, M ^b   Korabiowska, M ^a   Kuhn, W ^a   Schauer, A ^a  

^a UNIVERSITY OF GÖTTINGEN   (Germany)

^b UNIVERSITY OF ULM   (Germany)

Author keywords

Ki 67 antigen; Mib 1; Ovarian cancer; Prognosis; Proliferation

Indexed keywords

MONOCLONAL ANTIBODY KI 67;

ADOLESCENT; ADULT; ARTICLE; CANCER STAGING; CELL PROLIFERATION; CONTROLLED STUDY; FEMALE; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MAJOR CLINICAL STUDY; MULTIVARIATE ANALYSIS; OVARY CANCER; PRIORITY JOURNAL; PROGNOSIS; SURVIVAL TIME; TUMOR DIFFERENTIATION;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; ANTIBODIES, MONOCLONAL; ANTIGENS, NEOPLASM; ANTIGENS, NUCLEAR; CELL DIVISION; EPITOPES; FEMALE; HUMANS; KI-67 ANTIGEN; MIDDLE AGED; NEOPLASM STAGING; NUCLEAR PROTEINS; OVARIAN NEOPLASMS; SURVIVAL RATE;

EID: 0031055966     PISSN: 02507005     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (30)

1. Sorbe B, Frankendal B, Veress B: Importance of histologic grading in the prognosis of epithelial ovarian carcinoma. Obstet Gynecol 59: 576-582, 1982.
2. Hacker NF, Berek JS, Lagasse LD, Nieberg RK, Elashoff RM: Primary cytoreductive surgery for epithelial ovarian cancer. Obstet Gynecol 61: 413-420, 1983.
3. Sigurdsson K, Alm P, Gullberg B: Prognostic factors in malignant epithelial tumors. Gynecol Oncol 15: 370-380, 1983.
4. Malkasian GC, Melton J, O'Brien PC, Greene MH: Prognostic significance of histologic classification and grading of epithelial malignancies of the ovary. Am J Obst Gynecol 149: 274-284, 1984.
5. Meerpohl HG: Prognosefaktoren des Ovarialkarzinoms. Onkologie 8: 296-304, 1985.
6. Swenerton KD, Hislop TG, Spinelli J, LeRiche JC, Yang N, Boyes DA: Ovarian carcinoma: a multivariative analysis of prognostic factors. Obstet Gynecol 65: 264-270, 1985.
7. Russel P: Common epithelial tumors of the ovary. In: Obstetrical and gynaecological Pathology (Fox H, ed.). Edinburgh, Churchill Livingstone, 1987, pp 555-622.
8. Rath W, Meden H: The therapeutic conzept in ovarian cancer. Med Klinik 86: 263-268, 1991.
9. Slamon DJ, Godolphin W, Jones LA, Holt JA, Wong SG, Keith DE, Levin WJ, Stuart SG, Udove S, Ulrich A, Press MF: Studies of the HER-2/neu protooncogene in human breast and ovarian cancer. Science 244: 707-712, 1989.
10. Meden H, Marx D, Rath W, Kron M, Fattahi-Meibodi A, Hinney B, Kuhn W, Schauer A: Overexpression of the oncogene c-erb-B2 in primary ovarian cancer: evaluation of the prognostic value in a cox. proportional hazards multiple regression. Int J Gynecol Pathol 13: 45-53, 1994.
11. Berchuck A, Kamel A, Whitaker R, Kerns B, Olt G, Kinney R, Woper JT, Dodge R, Clarke-Pearson DL, Marks P: Overexpression of HER2/neu is associated with poor survival in advanced epithelial ovarian cancer. Cancer Res 50: 4087-4091, 1990.
12. Hall PA, Levison DA: Review: assessment of cell proliferation in histological material. J Clin Pathol 43: 184-192, 1990.
13. Gerdes J: An immunohistochemical method for estimating cell growth fraction in rapid histopathological diagnosis during surgery. Int J Cancer 35: 169-171, 1985.
14. Schwartz BR, Pinkus G, Bacus S, Tder M, Weinberg DS: Cell proliferation in non-Hodgins lymphoma. Am J Pathol 134: 327-336, 1989.
15. Zehr RJ, Bauer TW, Marks KE, Weltevreden A: Ki-67 and grading of malignant fibrous histiocytomas. Cancer 66: 1984-1990, 1990.
16. Gerdes J, Lelle RJ, Pickartz H, Heidenreich W, Schwarting R, Kurtsiefer L, Stauch G, Stein H: Growth fractions in breast cancers determined in situ with the monoclonal antibody Ki-67. J Clin Pathol 39: 977-980, 1986.
17. Pinder SE, Wencyk P, Sibbering DM, Bell JA, Elston CW, Nicholson R, Robertson JF, Blamey RW, Ellis IO:. Assessment of the new proliferation marker MIB1 in breast carcinoma using image analysis: associations with other prognostic factors and survival. Br J Cancer 71: 146-149, 1995.
18. Catoretti G, Becker MH, Duchrow M, Schlüter C, Galle J, Gerdes J: Monoclonal antibodies against recombinant parts of the Ki-67 antigen (MIB1 and MIB 3) detect proliferating cells in microwave-processed formalin-fixed paraffin sections. J Pathol 168; 357-363, 1992.
19. Key G, Becker MHG, Duchrow C, Schlüter C, Gerdes J: New ki-67 equivalent murine monclonal anitbodies (MIB 1-3) prepared against recombinant parts of thre ki-67 antigen. Anal Cell Pathol 4: 181, 1992.
20. Serov SF, Scully RE, Sobin LH: Histological typing of ovarian tumors. WHO International histological classification of tumors 9: 37-42, 1973.
21. Kaplan EL, Meier P: Nonparametric estimation from incomplete observations. J Am Stat Assoc 53: 457-8023, 1958.
22. Cox Dr: Regression modells and life-tables (with discussion). J Stat Soc B 34: 187-220, 1972.
23. Kuwashima Y, Uehara T, Kurosumi M, Shiromizu K, Matsuzawa M, Kishi K: Cell dynamics of undifferentiated carcinomas of the ovary. Immunohistochemical estimation of their growth fraction and apoptotic status. Eur J Gynaecol Oncol 16: 268-273, 1995.
24. Wong WSF, Tattersall MHN: Immunohistochemical determination of tumor growth fraction in human ovarian carcinomas. Br J Obstet Gynecol 96: 720-724, 1989.
25. Jordan PA, Kerns BJ, Pence JC, Kohler MF, Bast RC Jr, Kinney RB, Berchuck A: Determination of proliferation index in advanced ovarian cancer using quantitative image analysis. Am J Clin Pathol 99: 736-740, 1993.
26. Kerns BM, Jordan PA; Faerman LL; Berchuck A; Bast RC Jr; Layfield LJ: Determination of proliferation index with MIB-1 in advanced ovarian cancer using quantitative image analysis. Am J Clin Pathol 101: 192-197, 1994.
27. Isola J, Kallioniemi OP, Korte JM, Wahlstrom T, Aine R, Helle M, Helin H: Steroid receptors and Ki-67 reactivity in ovarian cancer and in normal ovary. Correlation with DNA flow cytometry, biochemical receptor assay, and patient survival. J Pathol 162: 295-301, 1990.
28. Garzetti GG, Ciavattini A, Goteri G, De-Nictolis M, Stramazzotti D, Lucarini G, Biagini G: Ki67 antigen immunostaining (MIB 1 monoclonal antibody) in serous ovarian tumors: index of proliferative activity with prognostic significance. Gynecol Oncol 56: 169-174, 1995.
29. Henriksen R, Strang P, Backstrom T, Wilander E, Tribukait B, Oberg K: Ki-67 immunostaining and DNA flow cytometry as prognostic factors in epithelial ovarian cancers. Anticancer Res 14: 603-608, 1994.
30. Baak JPA, Langley FA, Talerman A, Delemare JFM: Interpathologist and intrapathologist disagreement in ovarian tumor grading and typing. Anal Quant Cytol Histol 8: 354-357, 1986.